Conclusion of Evaluation Project
ValiRx concludes Dual Kinase evaluation project with Imperial College London and returns it to university researchers.
Select text to share a quote on X · sign in to keep highlights & notes in your VAL notes
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update at the conclusion of the Evaluation project from Imperial College London announced on 21 March 2024.
On entering the collaboration agreement with Imperial College London in March 2024, the Company synthesised, tested and profiled drug candidates from the Dual Kinase series in comparison with gold standard therapeutics in a range of tests.
Although initial results showed promise, the development programme is at an early stage, and the Company has decided to return the project to the university researchers for further development, with no further financial commitment from the Company. The parties have agreed to terminate the current collaboration agreement and revert responsibility for maintaining the intellectual property to Imperial College London.
Mark Eccleston, CEO of ValiRx commented "Working alongside the Imperial College London team on this project has been an engaging experience, and although we are not in a position to progress with this lead series of molecules at this stage, we look forward to retaining close contact with the team at Imperial to hear further updates on these and other projects which could lead to future agreements."
| Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub | https://valirx.com/link/Ve96or |
| ValiRx plc Dr Mark Eccleston, CEO | Tel: +44 115 784 0025 www.valirx.com Mark.Eccleston@valirx.com |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti | Tel: +44 (0) 20 7213 0880 |
| Shard Capital Partners LLP (Sole Broker) Damon Heath | Tel: +44 (0) 20 7186 9000 |
| V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director | +44 (0) 115 787 0206 www.vformation.biz lucy@vformation.biz sue@vformation.biz |
Subscribe to our news alert service: https://valirx.com/s/f298d1
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.